ID   TEBP_HUMAN              Reviewed;         160 AA.
AC   Q15185; A8K7D0; B4DHP2; B4DP11; B4DP21; Q8WU70;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Prostaglandin E synthase 3;
DE            EC=5.3.99.3 {ECO:0000269|PubMed:10922363};
DE   AltName: Full=Cytosolic prostaglandin E2 synthase;
DE            Short=cPGES;
DE   AltName: Full=Hsp90 co-chaperone;
DE   AltName: Full=Progesterone receptor complex p23;
DE   AltName: Full=Telomerase-binding protein p23;
GN   Name=PTGES3; Synonyms=P23, TEBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROGESTERONE
RP   RECEPTOR-BINDING.
RC   TISSUE=Testis;
RX   PubMed=8114727; DOI=10.1128/MCB.14.3.1956;
RA   Johnson J.L., Beito T.G., Krco C.J., Toft D.O.;
RT   "Characterization of a novel 23-kilodalton protein of unactive
RT   progesterone receptor complexes.";
RL   Mol. Cell. Biol. 14:1956-1963(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2; 3 AND 4).
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, and Urinary bladder;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 13-65; 72-88 AND 96-122, PHOSPHORYLATION AT
RP   SER-113, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [7]
RP   INTERACTION WITH TERT, AND FUNCTION AS A CO-CHAPERONE IN TELOMERASE
RP   HOLOENZYME ASSEMBLY.
RX   PubMed=11274138; DOI=10.1074/jbc.C100055200;
RA   Forsythe H.L., Jarvis J.L., Turner J.W., Elmore L.W., Holt S.E.;
RT   "Stable association of hsp90 and p23, but Not hsp70, with active human
RT   telomerase.";
RL   J. Biol. Chem. 276:15571-15574(2001).
RN   [8]
RP   FUNCTION AS A CHAPERONE.
RX   PubMed=12077419; DOI=10.1126/science.1073051;
RA   Freeman B.C., Yamamoto K.R.;
RT   "Disassembly of transcriptional regulatory complexes by molecular
RT   chaperones.";
RL   Science 296:2232-2235(2002).
RN   [9]
RP   FUNCTION AS A PROSTAGLANDIN SYNTHASE, BIOPHYSICOCHEMICAL PROPERTIES,
RP   CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=10922363; DOI=10.1074/jbc.M003504200;
RA   Tanioka T., Nakatani Y., Semmyo N., Murakami M., Kudo I.;
RT   "Molecular identification of cytosolic prostaglandin E2 synthase that
RT   is functionally coupled with cyclooxygenase-1 in immediate
RT   prostaglandin E2 biosynthesis.";
RL   J. Biol. Chem. 275:32775-32782(2000).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-118; SER-148
RP   AND SER-151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Pituitary;
RX   PubMed=16807684; DOI=10.1007/s11102-006-8916-x;
RA   Beranova-Giorgianni S., Zhao Y., Desiderio D.M., Giorgianni F.;
RT   "Phosphoproteomic analysis of the human pituitary.";
RL   Pituitary 9:109-120(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Prostate cancer;
RX   PubMed=17487921; DOI=10.1002/elps.200600782;
RA   Giorgianni F., Zhao Y., Desiderio D.M., Beranova-Giorgianni S.;
RT   "Toward a global characterization of the phosphoproteome in prostate
RT   cancer cells: identification of phosphoproteins in the LNCaP cell
RT   line.";
RL   Electrophoresis 28:2027-2034(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-148 AND
RP   SER-151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113; SER-148 AND
RP   SER-151, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-33, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113 AND SER-118, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-44; SER-85 AND SER-113,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH EGLN1.
RX   PubMed=24711448; DOI=10.1074/jbc.M113.541227;
RA   Song D., Li L.S., Arsenault P.R., Tan Q., Bigham A.W.,
RA   Heaton-Johnson K.J., Master S.R., Lee F.S.;
RT   "Defective Tibetan PHD2 binding to p23 links high altitude adaption to
RT   altered oxygen sensing.";
RL   J. Biol. Chem. 289:14656-14665(2014).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-113; SER-148 AND
RP   SER-151, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-130 (ISOFORM
RP   4), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [30]
RP   INTERACTION WITH HSP90AA1; FLCN; FNIP1 AND FNIP2.
RX   PubMed=27353360; DOI=10.1038/ncomms12037;
RA   Woodford M.R., Dunn D.M., Blanden A.R., Capriotti D., Loiselle D.,
RA   Prodromou C., Panaretou B., Hughes P.F., Smith A., Ackerman W.,
RA   Haystead T.A., Loh S.N., Bourboulia D., Schmidt L.S.,
RA   Marston Linehan W., Bratslavsky G., Mollapour M.;
RT   "The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and
RT   enhance drug binding.";
RL   Nat. Commun. 7:12037-12037(2016).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 1-125.
RX   PubMed=10811660; DOI=10.1074/jbc.M003410200;
RA   Weaver A.J., Sullivan W.P., Felts S.J., Owen B.A.L., Toft D.O.;
RT   "Crystal structure and activity of human p23, a heat shock protein 90
RT   co-chaperone.";
RL   J. Biol. Chem. 275:23045-23052(2000).
CC   -!- FUNCTION: Cytosolic prostaglandin synthase that catalyzes the
CC       oxidoreduction of prostaglandin endoperoxide H2 (PGH2) to
CC       prostaglandin E2 (PGE2) (PubMed:10922363). Molecular chaperone
CC       that localizes to genomic response elements in a hormone-dependent
CC       manner and disrupts receptor-mediated transcriptional activation,
CC       by promoting disassembly of transcriptional regulatory complexes
CC       (PubMed:11274138, PubMed:12077419). Facilitates HIF alpha proteins
CC       hydroxylation via interaction with EGLN1/PHD2, leading to recruit
CC       EGLN1/PHD2 to the HSP90 pathway (PubMed:24711448).
CC       {ECO:0000269|PubMed:10922363, ECO:0000269|PubMed:11274138,
CC       ECO:0000269|PubMed:12077419, ECO:0000269|PubMed:24711448}.
CC   -!- CATALYTIC ACTIVITY: (5Z,13E)-(15S)-9-alpha,11-alpha-epidioxy-15-
CC       hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-11-alpha,15-
CC       dihydroxy-9-oxoprosta-5,13-dienoate.
CC       {ECO:0000269|PubMed:10922363}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=14 uM for PGH2 {ECO:0000269|PubMed:10922363};
CC         Vmax=190 nmol/min/mg enzyme toward PGH2
CC         {ECO:0000269|PubMed:10922363};
CC   -!- PATHWAY: Lipid metabolism; prostaglandin biosynthesis.
CC       {ECO:0000269|PubMed:10922363}.
CC   -!- SUBUNIT: Binds to the progesterone receptor (PubMed:8114727).
CC       Interacts with TERT; the interaction, together with HSP90AA1, is
CC       required for correct assembly and stabilization of the telomerase
CC       holoenzyme complex (PubMed:11274138). Interacts (via PXLE motif)
CC       with EGLN1/PHD2, recruiting EGLN1/PHD2 to the HSP90 pathway to
CC       facilitate HIF alpha proteins hydroxylation (PubMed:24711448).
CC       Interacts with HSP90AA1, FLCN, FNIP1 and FNIP2 (PubMed:27353360).
CC       {ECO:0000269|PubMed:11274138, ECO:0000269|PubMed:24711448,
CC       ECO:0000269|PubMed:27353360, ECO:0000269|PubMed:8114727}.
CC   -!- INTERACTION:
CC       Q9UKV8:AGO2; NbExp=3; IntAct=EBI-1049387, EBI-528269;
CC       P07900:HSP90AA1; NbExp=6; IntAct=EBI-1049387, EBI-296047;
CC       O14654:IRS4; NbExp=2; IntAct=EBI-1049387, EBI-356594;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q3ZBF7}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15185-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15185-2; Sequence=VSP_055363;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q15185-3; Sequence=VSP_055364;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q15185-4; Sequence=VSP_055365;
CC         Note=No experimental confirmation available. Contains a
CC         phosphoserine at position 130. {ECO:0000244|PubMed:24275569};
CC   -!- DOMAIN: The PXLE motif mediates interaction with EGLN1/PHD2.
CC       {ECO:0000269|PubMed:24711448}.
CC   -!- SIMILARITY: Belongs to the p23/wos2 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L24804; AAA18537.1; -; mRNA.
DR   EMBL; AK291945; BAF84634.1; -; mRNA.
DR   EMBL; AK295208; BAG58204.1; -; mRNA.
DR   EMBL; AK298147; BAG60423.1; -; mRNA.
DR   EMBL; AK298160; BAG60433.1; -; mRNA.
DR   EMBL; AC117378; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471054; EAW96953.1; -; Genomic_DNA.
DR   EMBL; CH471054; EAW96958.1; -; Genomic_DNA.
DR   EMBL; BC003005; AAH03005.1; -; mRNA.
DR   EMBL; BC021167; AAH21167.1; -; mRNA.
DR   CCDS; CCDS31836.1; -. [Q15185-1]
DR   CCDS; CCDS61158.1; -. [Q15185-2]
DR   CCDS; CCDS61159.1; -. [Q15185-3]
DR   CCDS; CCDS61160.1; -. [Q15185-4]
DR   PIR; A56211; A56211.
DR   RefSeq; NP_001269530.1; NM_001282601.1. [Q15185-4]
DR   RefSeq; NP_001269531.1; NM_001282602.1. [Q15185-3]
DR   RefSeq; NP_001269532.1; NM_001282603.1. [Q15185-2]
DR   RefSeq; NP_001269533.1; NM_001282604.1.
DR   RefSeq; NP_001269534.1; NM_001282605.1.
DR   RefSeq; NP_006592.3; NM_006601.6. [Q15185-1]
DR   UniGene; Hs.50425; -.
DR   PDB; 1EJF; X-ray; 2.49 A; A/B=1-125.
DR   PDB; 1LG0; Model; -; A=1-110.
DR   PDBsum; 1EJF; -.
DR   PDBsum; 1LG0; -.
DR   DisProt; DP00358; -.
DR   ProteinModelPortal; Q15185; -.
DR   SMR; Q15185; -.
DR   BioGrid; 115952; 95.
DR   DIP; DIP-279N; -.
DR   IntAct; Q15185; 42.
DR   MINT; MINT-5000397; -.
DR   STRING; 9606.ENSP00000262033; -.
DR   ChEMBL; CHEMBL3341580; -.
DR   DrugBank; DB05036; Grn163l.
DR   SwissLipids; SLP:000000831; -.
DR   iPTMnet; Q15185; -.
DR   PhosphoSitePlus; Q15185; -.
DR   SwissPalm; Q15185; -.
DR   EPD; Q15185; -.
DR   MaxQB; Q15185; -.
DR   PaxDb; Q15185; -.
DR   PeptideAtlas; Q15185; -.
DR   PRIDE; Q15185; -.
DR   TopDownProteomics; Q15185-1; -. [Q15185-1]
DR   DNASU; 10728; -.
DR   Ensembl; ENST00000262033; ENSP00000262033; ENSG00000110958. [Q15185-1]
DR   Ensembl; ENST00000414274; ENSP00000405299; ENSG00000110958. [Q15185-3]
DR   Ensembl; ENST00000436399; ENSP00000402385; ENSG00000110958. [Q15185-2]
DR   Ensembl; ENST00000448157; ENSP00000414892; ENSG00000110958. [Q15185-4]
DR   GeneID; 10728; -.
DR   KEGG; hsa:10728; -.
DR   UCSC; uc001slu.6; human. [Q15185-1]
DR   CTD; 10728; -.
DR   DisGeNET; 10728; -.
DR   GeneCards; PTGES3; -.
DR   HGNC; HGNC:16049; PTGES3.
DR   HPA; CAB034319; -.
DR   HPA; HPA038672; -.
DR   HPA; HPA038673; -.
DR   MIM; 607061; gene.
DR   neXtProt; NX_Q15185; -.
DR   OpenTargets; ENSG00000110958; -.
DR   PharmGKB; PA142671118; -.
DR   eggNOG; KOG3158; Eukaryota.
DR   eggNOG; ENOG41121RT; LUCA.
DR   GeneTree; ENSGT00510000046493; -.
DR   HOGENOM; HOG000177563; -.
DR   HOVERGEN; HBG002143; -.
DR   InParanoid; Q15185; -.
DR   KO; K15730; -.
DR   PhylomeDB; Q15185; -.
DR   TreeFam; TF315077; -.
DR   BioCyc; MetaCyc:HS03359-MONOMER; -.
DR   Reactome; R-HSA-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   Reactome; R-HSA-3371511; HSF1 activation.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-8937144; Aryl hydrocarbon receptor signalling.
DR   SIGNOR; Q15185; -.
DR   UniPathway; UPA00662; -.
DR   ChiTaRS; PTGES3; human.
DR   EvolutionaryTrace; Q15185; -.
DR   GeneWiki; PTGES3; -.
DR   GenomeRNAi; 10728; -.
DR   PRO; PR:Q15185; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000110958; -.
DR   CleanEx; HS_PTGES3; -.
DR   ExpressionAtlas; Q15185; baseline and differential.
DR   Genevisible; Q15185; HS.
DR   GO; GO:0000781; C:chromosome, telomeric region; IC:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; IDA:UniProtKB.
DR   GO; GO:0070182; F:DNA polymerase binding; IPI:BHF-UCL.
DR   GO; GO:0051879; F:Hsp90 protein binding; IPI:CAFA.
DR   GO; GO:0050220; F:prostaglandin-E synthase activity; IDA:UniProtKB.
DR   GO; GO:0003720; F:telomerase activity; IDA:UniProtKB.
DR   GO; GO:0051082; F:unfolded protein binding; IDA:UniProtKB.
DR   GO; GO:0070389; P:chaperone cofactor-dependent protein refolding; IDA:UniProtKB.
DR   GO; GO:0051131; P:chaperone-mediated protein complex assembly; IMP:CAFA.
DR   GO; GO:0019371; P:cyclooxygenase pathway; TAS:Reactome.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0051973; P:positive regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0001516; P:prostaglandin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IMP:CAFA.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:1905323; P:telomerase holoenzyme complex assembly; IDA:BHF-UCL.
DR   GO; GO:0000723; P:telomere maintenance; TAS:UniProtKB.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; IDA:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   Gene3D; 2.60.40.790; -; 1.
DR   InterPro; IPR007052; CS_dom.
DR   InterPro; IPR008978; HSP20-like_chaperone.
DR   Pfam; PF04969; CS; 1.
DR   SUPFAM; SSF49764; SSF49764; 1.
DR   PROSITE; PS51203; CS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chaperone;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Isomerase;
KW   Lipid biosynthesis; Lipid metabolism; Phosphoprotein;
KW   Prostaglandin biosynthesis; Prostaglandin metabolism;
KW   Reference proteome.
FT   CHAIN         1    160       Prostaglandin E synthase 3.
FT                                /FTId=PRO_0000218952.
FT   DOMAIN        1     90       CS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00547}.
FT   MOTIF       157    160       PXLE motif.
FT                                {ECO:0000303|PubMed:24711448}.
FT   COMPBIAS    108    160       Asp/Glu-rich.
FT   MOD_RES      33     33       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      44     44       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      85     85       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     100    100       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9R0Q7}.
FT   MOD_RES     113    113       Phosphoserine.
FT                                {ECO:0000244|PubMed:16807684,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:17487921,
FT                                ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|Ref.6}.
FT   MOD_RES     118    118       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     148    148       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     151    151       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ      63     95       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055363.
FT   VAR_SEQ      96    125       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055364.
FT   VAR_SEQ     126    146       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055365.
FT   STRAND        6     10       {ECO:0000244|PDB:1EJF}.
FT   STRAND       12     19       {ECO:0000244|PDB:1EJF}.
FT   STRAND       24     32       {ECO:0000244|PDB:1EJF}.
FT   STRAND       35     42       {ECO:0000244|PDB:1EJF}.
FT   TURN         43     46       {ECO:0000244|PDB:1EJF}.
FT   STRAND       47     57       {ECO:0000244|PDB:1EJF}.
FT   STRAND       59     68       {ECO:0000244|PDB:1EJF}.
FT   STRAND       73     81       {ECO:0000244|PDB:1EJF}.
FT   STRAND       87     92       {ECO:0000244|PDB:1EJF}.
FT   STRAND       99    101       {ECO:0000244|PDB:1EJF}.
FT   TURN        103    105       {ECO:0000244|PDB:1EJF}.
SQ   SEQUENCE   160 AA;  18697 MW;  23538BB9D7AFD73F CRC64;
     MQPASAKWYD RRDYVFIEFC VEDSKDVNVN FEKSKLTFSC LGGSDNFKHL NEIDLFHCID
     PNDSKHKRTD RSILCCLRKG ESGQSWPRLT KERAKLNWLS VDFNNWKDWE DDSDEDMSNF
     DRFSEMMNNM GGDEDVDLPE VDGADDDSQD SDDEKMPDLE
//
